Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned a consensus rating of “Buy” from the fourteen ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $117.8182.

A number of brokerages have recently commented on DNTH. Oppenheimer increased their price objective on Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research report on Monday, March 9th. Wells Fargo & Company began coverage on Dianthus Therapeutics in a research report on Thursday, March 19th. They set an “overweight” rating and a $135.00 price objective for the company. Robert W. Baird increased their price objective on Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 10th. Truist Financial increased their price objective on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 9th. Finally, Raymond James Financial raised Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $63.00 to $123.00 in a research report on Tuesday, March 10th.

Insiders Place Their Bets

In other news, CAO Edward Carr sold 43,682 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marino Garcia sold 122,918 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $10,016,587.82. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 323,021 shares of company stock worth $26,564,008. 3.02% of the stock is currently owned by corporate insiders.

Institutional Trading of Dianthus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. boosted its position in shares of Dianthus Therapeutics by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock worth $3,135,000 after buying an additional 139 shares during the period. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics in the first quarter worth $32,000. Virtus Investment Advisers LLC boosted its position in shares of Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after buying an additional 416 shares during the period. Parkside Financial Bank & Trust boosted its position in shares of Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after buying an additional 540 shares during the period. Finally, Royal Bank of Canada boosted its position in shares of Dianthus Therapeutics by 36.9% in the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after buying an additional 542 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $86.16 on Monday. Dianthus Therapeutics has a one year low of $16.64 and a one year high of $96.50. The stock has a fifty day moving average of $84.70 and a 200-day moving average of $58.51. The company has a market capitalization of $4.71 billion, a PE ratio of -20.86 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. As a group, research analysts forecast that Dianthus Therapeutics will post -3.82 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.